Table 1.
Overview of diagnosis representation in cohorts.
| Agilent CNS cohort | |
|---|---|
| Total number of samples | 97 |
| Diagnosis groups | |
| Medulloblastoma | 32 |
| Posterior fossa ependymoma | 18 |
| Diffuse midline glioma, H3 K27-altered | 10 |
| Pilocytic astrocytoma | 10 |
| Atypical teratoid/rhabdoid tumor | 6 |
| Supratentorial ependymoma | 5 |
| Astroblastoma, MN1-altered | 4 |
| Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype | 4 |
| Others | 8 |
| Agilent Sarcoma cohort | |
| Total number of samples | 52 |
| Diagnosis groups | |
| Ewing sarcoma | 12 |
| Osteosarcoma | 9 |
| Alveolar rhabdomyosarcoma | 7 |
| Embryonal rhabdomyosarcoma | 4 |
| Undifferentiated round cell sarcomas with CIC or BCOR alteration | 4 |
| Synovial sarcoma | 3 |
| Others | 13 |
| Illumina cohort | |
| Total number of samples | 40 |
| Diagnosis groups | |
| Medulloblastoma | 15 |
| Posterior fossa ependymoma | 8 |
| Diffuse midline glioma, H3 K27-altered | 5 |
| Others | 12 |